OneMedNet Integrates Navidence's CODefs to Expedite Real-World Data Analysis

Event summary

  • OneMedNet and Navidence have formed a strategic collaboration to integrate Navidence’s Computable Operational Definitions (CODefs) with OneMedNet’s iRWD™ platform.
  • The collaboration aims to streamline real-world data analysis for pharmaceutical companies, accelerating study design and reducing data procurement costs.
  • Navidence’s CODefs standardize data queries across datasets, while OneMedNet provides a large-scale multimodal data infrastructure.
  • The Real-World Data market is projected to grow from $1.88 billion in 2025 to $6.37 billion by 2034, exhibiting a 14.54% CAGR.

The big picture

The collaboration reflects the growing pressure on pharmaceutical companies to leverage real-world data for regulatory approvals and AI model training. Standardizing data analysis through CODefs addresses a key bottleneck in the RWD workflow, potentially accelerating drug development timelines and reducing costs. This partnership positions both companies to capitalize on the expanding RWD market, but also intensifies competition in a rapidly evolving space.

What we're watching

Execution Risk
The success of this collaboration hinges on the seamless integration of Navidence’s CODefs with OneMedNet’s iRWD™ platform, and the ability to demonstrate tangible efficiency gains for customers.
Regulatory Scrutiny
Increased reliance on real-world evidence will likely draw greater scrutiny from regulatory bodies like the FDA and EMA, requiring OneMedNet to maintain robust data governance and validation processes.
Competitive Landscape
The RWD market is becoming increasingly crowded; OneMedNet must differentiate its offering beyond standardized definitions to retain and attract customers.

Related topics

Pharmaceuticals CAGR